HealthCap

The firm was founded in 1996 by Björn Odlander{{cite web|title=Björn Odlander|url=http://investing.businessweek.com/research/stocks/private/person.asp?personId=76432&privcapId=183871&previousCapId=183871&previousTitle=HealthCap|archive-url=https://archive.today/20130119015715/http://investing.businessweek.com/research/stocks/private/person.asp?personId=76432&privcapId=183871&previousCapId=183871&previousTitle=HealthCap|url-status=dead|archive-date=January 19, 2013|publisher=Bloomberg Businessweek}} and Peder Fredrikson,{{cite web|title=Peder Fredrikson|url=http://investing.businessweek.com/research/stocks/private/person.asp?personId=76430&privcapId=183871&previousCapId=183871&previousTitle=HealthCap|archive-url=https://archive.today/20130110173659/http://investing.businessweek.com/research/stocks/private/person.asp?personId=76430&privcapId=183871&previousCapId=183871&previousTitle=HealthCap|url-status=dead|archive-date=January 10, 2013|publisher=Bloomberg Businessweek}} and the first fund was started the same year.{{Cite web |title="Många bolag är utsvultna på kapital". Veckans Affärer. |url=https://www.di.se/amnen/veckans-affarer/}} As of 2023, HealthCap has established eight funds and financed more than 125 companies, where more than 45 have been taken public on nine different markets. The most recent fund, HealthCap VIII, was established in 2019.

HealthCap has approximately 25 employees out of which thirteen are partners. The team combines venture capital investing experience with competences and work experiences from small as well as large companies across the healthcare industry, spanning disciplines of scientific research, drug development, clinical practice, investment banking, and industry management.{{Citation needed|date=July 2022}}

{{history of private equity and venture capital}}

HealthCap has raised eight main funds. Investors in HealthCap funds include, among others, European Investment Fund, Skandia Life Insurance, the 4th and 6th Swedish National Pension Funds, The Kresge Foundation, Mayo Clinic, Northwestern University, University of Michigan, Vanderbilt University and Washington University. HealthCap has committed capital exceeding EUR 1 billion.{{cite web|url=http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=183871|archive-url=https://web.archive.org/web/20110605010258/http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=183871|url-status=dead|archive-date=June 5, 2011|title=Company Overview of HealthCap|publisher=Bloomberg Businessweek}}{{cite web|url=http://www.altassets.net/private-equity-news/nordic-healthcap-announces-final-close-of-its-fourth-biotech-fund-at-322m.html|title=Nordic HealthCap announces final close of its fourth biotech fund at $322m|date=30 November 2001 |publisher=The Alternative Assets Network}}

HealthCap invests in companies developing disruptive technologies that hold the potential to change clinical practice. Over the years HealthCap has invested in more than 125 companies. The portfolio companies have developed more than 20 pharmaceutical products and over 40 med-tech products to the market.{{cite web|title=HealthCap website|url=http://www.healthcap.eu/company/|publisher=HealthCap}} Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies addressing life-threatening diseases. Examples of technologies financed by HealthCap are:

• {{Flag icon|Switzerland}} Pulmonary hypertension therapy developed by Actelion. The company was acquired by J&J in 2017.{{Cite web |date=2017-08-03 |title=Expert Insights: Johnson & Johnson's Actelion buy establishes a Clear Leader in the Pulmonary Arterial Hypertension Market |url=https://www.clinicaltrialsarena.com/news/expert-insights-johnson-johnsons-actelion-buy-establishes-a-clear-leader-in-the-pulmonary-arterial-hypertension-market-5890456-2/ |access-date=2022-05-17 |website=Clinical Trials Arena |language=en-US}}
• {{Flag icon|NOR}} Xofigo® developed by Algeta{{cite web|title=Algeta ASA Raises Euro 23 Million in Series A Round|url=http://crm.sys-con.com/node/125317|publisher=CRM|access-date=2012-12-14|archive-date=2016-03-04|archive-url=https://web.archive.org/web/20160304042221/http://crm.sys-con.com/node/125317|url-status=dead}} for treatment of bone metastasis in prostate cancer.
• {{Flag icon|USA}} A range of drugs in development for rare and ultra-rare genetic diseases by Ultragenyx.
• {{Flag icon|Sweden}} Restylane, an injectable filler developed by Q-Med. The company was acquired by Galderma in 2011.{{Cite web |title="HealthCap ökar sitt ägande i Q-Med". Q-Med |url=https://news.cision.com/se}}
• {{Flag icon|USA}} Trans-femoral aortic valve replacement developed by CoreValve{{cite web|title=Medtronic Buying CoreValve for $700 Million+|url=http://privatemarkets.thomsonreuters.com/medtronic-buying-corevalve-for-$700-million+/20020285.article|archive-url=https://archive.today/20130204155607/http://privatemarkets.thomsonreuters.com/medtronic-buying-corevalve-for-$700-million+/20020285.article|url-status=dead|archive-date=February 4, 2013|publisher=Thomson Reuters}} that evades the need for open heart surgery when replacing a malfunctioning heart valve.
• {{Flag icon|SWE}} Injectable synthetic bone substitute, Cerament, to enhance bone remodeling and fracture healing developed by BoneSupport AB.
• {{Flag icon|SWE}} WTX101, an orphan drug currently in development by Wilson Therapeutics for the treatment of Wilson's disease.[http://www.lifesciencesweden.se/finansiering-eller-stod/wilson-therapeutics-far-mangmiljonbelopp/] {{Webarchive|url=https://web.archive.org/web/20141104002418/http://www.lifesciencesweden.se/finansiering-eller-stod/wilson-therapeutics-far-mangmiljonbelopp/ |date=2014-11-04 }} "Wilson Therapeutics" Life Science Sweden. April 17, 2014.Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky, ML (2007). "Wilson's disease". Lancet 369 (9559): 397-408. Wilson Therapeutics was acquired by Alexion in 2018.

• [http://www.HealthCap.eu HealthCap website]

{{private equity firms}}

Category:Venture capital firms of Sweden

Category:Private equity and venture capital investors

Category:Private equity firms of Sweden

Category:Life sciences industry